Company research
MetaVia Inc.
CIK 1638287Updated Sep 26, 2026
SecurityMTVA · NASDAQ · equity
Historical securities (1)
NRBO · OTC · equity · closed Nov 27, 2024Name history
NeuroBo Pharmaceuticals, Inc. · through Nov 18, 2024Gemphire Therapeutics Inc. · through Dec 31, 2019
MTVA price & chart
Loading TradingView…
NASDAQ:MTVA on TradingView ↗About the company
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP-1 receptor agonists such as semaglutide. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a potential first-in-class drug candidate targeting G-protein-coupled receptor 119 (GPR119). In preclinical studies, vanoglipel demonstrated a positive metabolic effect on glucose and lipid control, and also proved differentiated hepatic benefits reducing hepatic steatosis, hepatic inflammation, and liver fibrosi…
In the news
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering News provided by MetaVia, Inc. Jan 15, 2026, 09:32 ET Share this article Share to X Share this article Share to X CAMBRIDGE, Mass. , Jan. 15, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA ) (MetaVia or the Company), a clin ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Other Events
Items 8.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 11,123,000Source | 16,260,000Source | 22,781,000Source | 33,534,000Source |
| Property, Plant and Equipment, NetUSD | 17,000Source | 34,000Source | 46,000Source | 2,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 10,278,000Source | 16,017,000Source | 22,435,000Source | 33,364,000Source |
| Assets, CurrentUSD | 10,875,000Source | 16,072,000Source | 22,512,000Source | 33,532,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 597,000Source | 55,000Source | 77,000Source | — |
| Operating Lease, Right-of-Use AssetUSD | 210,000Source | 133,000Source | 202,000Source | — |
| Other Assets, NoncurrentUSD | 21,000Source | 21,000Source | 21,000Source | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 5,790,000Source | 8,329,000Source | 6,096,000Source | 11,784,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 2,000Source | 9,000Source | 5,000Source | 25,000Source |
| Additional Paid in CapitalUSD | 154,161,000Source | 143,779,000Source | 124,945,000Source | 117,520,000Source |
| Retained Earnings (Accumulated Deficit)USD | -148,830,000Source | -135,857,000Source | -108,265,000Source | -95,795,000Source |
| Stockholders' Equity Attributable to ParentUSD | 5,333,000Source | 7,931,000Source | 16,685,000Source | 21,750,000Source |
| Liabilities and EquityUSD | 11,123,000Source | 16,260,000Source | 22,781,000Source | 33,534,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 5,648,000Source | 8,271,000Source | 5,960,000Source | 11,784,000Source |
| Operating Lease, Liability, CurrentUSD | 68,000Source | 78,000Source | 67,000Source | — |
| Accounts Payable, CurrentUSD | 1,060,000Source | 3,879,000Source | 821,000Source | 708,000Source |
| Operating Lease, Liability, NoncurrentUSD | 142,000Source | 58,000Source | 136,000Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | — | — | 4,414,000Source | 280,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 411,000Source | 538,000Source | 222,000Source | 854,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -2,819,000Source | 3,058,000Source | 113,000Source | -202,000Source |
| Deferred Income Tax Expense (Benefit)USD | -2,413,000Source | -8,401,000Source | -3,248,000Source | 26,331,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -15,701,000Source | -24,710,000Source | -10,799,000Source | -11,712,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -2,000Source | -8,000Source | -50,000Source | 8,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 2,000Source | 8,000Source | 50,000Source | — |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 12,000Source | 48,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 9,964,000Source | 18,300,000Source | -80,000Source | 28,681,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 10,278,000Source | 16,017,000Source | 22,435,000Source | 33,364,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 411,000Source | 538,000Source | 222,000Source | — |
| DepreciationUSD | 19,000Source | 20,000Source | 6,000Source | 20,000Source |
| Financing Interest ExpenseUSD | — | — | — | 2,191,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | — | -4,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | -75,000Source |
| General and Administrative ExpenseUSD | 6,906,000Source | 7,256,000Source | 6,728,000Source | 8,640,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -12,973,000Source | -27,592,000Source | -12,470,000Source | -13,967,000Source |
| Operating ExpensesUSD | 13,708,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | 735,000Source | 1,217,000Source | 3,416,000Source | 5,661,000Source |
| Payments of Financing CostsUSD | — | 1,651,000Source | 80,000Source | 3,569,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -13,708,000Source | -28,809,000Source | -15,886,000Source | -19,628,000Source |
| Other Nonoperating Income (Expense)USD | 735,000Source | 1,217,000Source | 3,416,000Source | 5,661,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -12,973,000Source | -27,592,000Source | -12,470,000Source | -13,967,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -12,973,000Source | -27,592,000Source | -12,470,000Source | -13,967,000Source |
| Earnings Per Share, BasicUSD per share | -7.35Source | -3.56Source | -2.46Source | -5.43Source |
| Earnings Per Share, DilutedUSD per share | -7.35Source | -3.56Source | -2.46Source | -5.43Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,766,026Source | 7,757,128Source | 5,071,101Source | 2,573,624Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,766,026Source | 7,757,128Source | 5,071,101Source | 2,573,624Source |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | — | 28,809,000Source | 15,886,000Source | 19,628,000Source |
| Financing Interest ExpenseUSD | — | — | — | 2,191,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | — | -4,000Source |
| General and Administrative ExpenseUSD | 6,906,000Source | 7,256,000Source | 6,728,000Source | 8,640,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -12,973,000Source | -27,592,000Source | -12,468,000Source | -14,559,000Source |
| Interest Income (Expense), NetUSD | 510,000Source | 920,000Source | 461,000Source | — |
| Operating ExpensesUSD | 13,708,000Source | — | — | — |
| Research and Development ExpenseUSD | 6,802,000Source | — | — | — |
Filing attachments
mtva-20260909xex99d1.htm · 8-K · 2026-09-09
EX-99.1 2 mtva-20260909xex99d1.htm EX-99.1 Exhibit 99.1 MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction Tissue Distribution Study Shows Highest Exposure in Adipose Tissue and Prolonged Retention Consistent with Once-Weekly Dosing Findings Provide Mechanistic Support for the Differentiated Profile of DA-1726 CAMBRIDGE, Mass., September 9, 2026 - MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on …
Read attachment ↗mtva-20260806xex99d1.htm · 8-K · 2026-08-06
EX-99.1 2 mtva-20260806xex99d1.htm EX-99.1 Exhibit 99.1 MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg in Ongoing Phase 1 Part 3 Study of DA-1726 16-Week Topline Data Expected in the Fourth Quarter of 2026 CAMBRIDGE, Mass., August 6, 2026 - MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today an…
Read attachment ↗mtva-20260806xex99d2.htm · 8-K · 2026-08-06
EX-99.2 3 mtva-20260806xex99d2.htm EX-99.2 Exhibit 99.2 1 MetaVia Inc. Transforming Cardiometabolic Diseases Investor Presentation August 2026 www.metaviatx.com Nasdaq: MTVA ───────────────────────────────── 2 Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current f…
Read attachment ↗tm2620006d1_ex99-1.htm · 8-K · 2026-07-09
EX-99.1 2 tm2620006d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 mg Topline Data Remains on Track for Fourth Quarter 2026 CAMBRIDGE, Mass., July 9, 2026 - MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announce…
Read attachment ↗mtva-20260608xex99d1.htm · 8-K · 2026-06-08
EX-99.1 2 mtva-20260608xex99d1.htm EX-99.1 Exhibit 99.1 MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential DA-1726 Phase 1, 48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau Vanoglipel Combined with Resmetirom Demonstrated Synergistic Hepatoprotective and Weight-Loss Effects in Preclinical MASH Model Vanoglipel Combined wit…
Read attachment ↗mtva-20260527xex99d1.htm · 8-K · 2026-05-27
EX-99.1 2 mtva-20260527xex99d1.htm EX-99.1 Exhibit 99.1 MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH 48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau Exploratory FibroScan Assessments Demonstrated Early Liver-Related Improvements Ongoing Phase 1 Part 3a/3b Titration Studies Continue to Evaluate Extended Treatment at Higher-Dose Levels CAMBRIDGE, Mass., May 27, 202…
Read attachment ↗